Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Statistical Methods for Analyzing Epidemiological Data

Statistical Methods for Analyzing Epidemiological Data

Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries.

CA: a cancer journal for clinicians·2026

Same author

Long-term effectiveness and overdiagnosis in the NHS breast screening programme: a cohort study with up to 33 years of follow-up.

British journal of cancer·2026

Same author

Socioeconomic disparities in site-specific cancer incidence and mortality: Golestan cohort study.

BMJ public health·2026

Same author

Tobacco product use among middle and high school students in the United States: National Youth Tobacco Survey, 2025.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2026

Same author

Colorectal cancer screening: An update to the American Cancer Society guideline, 2026.

CA: a cancer journal for clinicians·2026

Same author

Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2025

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Lung cancer statistics, 2023.

Tyler B Kratzer¹, Priti Bandi¹, Neal D Freedman²

¹Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.

|January 27, 2024

Summary

This summary is machine-generated.

Lung cancer mortality is declining faster than incidence, improving survival rates due to better treatments and earlier diagnosis. However, significant racial and geographic disparities persist, requiring targeted tobacco control and screening efforts.

Keywords:

cancer screening cancer statistics cancer surveillance lung cancer stage at diagnosis survival

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: Jul 4, 2025

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Oncology
Public Health
Epidemiology

Background:

Lung cancer remains the leading cause of cancer death in the US despite declining mortality rates.
Population-based data reveal trends in lung cancer incidence, diagnosis stage, survival, and mortality.

Purpose of the Study:

To examine recent trends in lung cancer incidence, stage at diagnosis, survival, and mortality.
To identify disparities in lung cancer outcomes among different demographic and geographic groups.

Main Methods:

Utilized population-based data from the National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries.
Analyzed trends in lung cancer mortality, incidence, survival rates, and stage at diagnosis over the past five years.
Compared incidence and mortality rates across different racial/ethnic groups and geographic regions.

Main Results:

Lung cancer mortality declined faster than incidence (5.0% vs. 2.6% annually for men, 4.3% vs. 1.1% annually for women).
Two-year relative survival improved by 1.4% annually, linked to treatment advances, increased access to care, and earlier diagnosis (localized-stage incidence rose 3.6% annually).
Significant disparities persist, with Native Americans experiencing the highest incidence and slowest decline, and high mortality rates in Mississippi and Kentucky.

Conclusions:

While progress has been made, lung cancer outcomes vary significantly by race and geography.
Targeted tobacco control, smoking-cessation treatments, and lung cancer screening are crucial for high-risk populations.
Addressing racial and geographic inequalities is essential for reducing lung cancer disparities.